Benzinga · Mar 31, 2026
NASDAQ · AKTX
Akari Therapeutics, Plc
Healthcare · Biotechnology
$9.76
Down-$0.31 (-3.03%)
Updated Sep 26, 2026, 6:05 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 4.22K
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $0.13 – $29.32
- Volume
- 71.54K
- Avg. volume
- 1.09M
Price performance
AKTX price history
1M range · 19 trading sessions · Daily adjusted prices
AKTX closed at $9.76 after 19 trading sessions, down 6.47% for the selected period.
- Last close
- $9.76
- Period change
- -6.47%
- Period low
- $9.16
- Period high
- $11.47
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $10.25 | $10.25 | $9.30 | $9.755 | 71.54K |
| Sep 24, 2026 | $9.90 | $10.10 | $9.565 | $10.06 | 47.39K |
| Sep 23, 2026 | $10.42 | $10.42 | $9.32 | $9.66 | 86.42K |
| Sep 22, 2026 | $9.2359 | $10.10 | $8.53 | $10.05 | 78.48K |
| Sep 21, 2026 | $9.52 | $9.81 | $9.0701 | $9.38 | 18.7K |
| Sep 18, 2026 | $9.63 | $10.125 | $9.16 | $9.16 | 63.65K |
| Sep 17, 2026 | $10.26 | $10.7413 | $9.39 | $9.875 | 126.51K |
| Sep 16, 2026 | $11.00 | $11.00 | $9.78 | $10.12 | 16.37K |
| Sep 15, 2026 | $11.05 | $11.05 | $10.00 | $10.25 | 27.59K |
| Sep 14, 2026 | $11.43 | $11.61 | $10.68 | $11.04 | 39.99K |
| Sep 11, 2026 | $10.51 | $11.50 | $10.51 | $11.30 | 135.28K |
| Sep 10, 2026 | $10.63 | $11.065 | $10.07 | $10.88 | 166.03K |
| Sep 9, 2026 | $10.89 | $12.15 | $10.0187 | $10.57 | 131.07K |
| Sep 8, 2026 | $11.32 | $12.04 | $10.75 | $10.96 | 128.54K |
| Sep 4, 2026 | $10.41 | $11.82 | $10.1703 | $11.47 | 108.91K |
| Sep 3, 2026 | $10.00 | $11.40 | $9.65 | $10.84 | 61.95K |
| Sep 2, 2026 | $10.09 | $10.40 | $9.60 | $10.15 | 46.5K |
| Sep 1, 2026 | $10.44 | $10.50 | $9.44 | $10.37 | 174.97K |
| Aug 31, 2026 | $10.62 | $11.40 | $9.75 | $10.43 | 81.4K |
Latest AKTX news
The latest Smart Investors Daily articles mentioning AKTX.
Stock researchCompany · Overview
AKTX research
Overview
Company profile and research snapshot.
Company profile
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $30.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 20, 2026 | Maxim Group | Buy | — |
| Apr 8, 2026 | Maxim Group | Hold | — |
| Apr 1, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 5, 2026 | Ladenburg Thalmann | Buy | — |
| Sep 9, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 30, 2026
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Benzinga · Mar 25, 2026
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · Mar 19, 2026
12 Health Care Stocks Moving In Thursday's Intraday Session
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
